ArticleJournal of clinical pharmacology2026
Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events.
Article in Journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Seasonal Variation in Reporting of Venous Thromboembolism in a Spontaneous Adverse Event Reporting System: Analysis of the Japanese Adverse Drug Event Report Database.Drug, healthcare and patient safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify the potential associations between intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibodies (ranibizumab, aflibercept, and brolucizumab) and cardiovascular or cerebrovascular adverse events using the Japanese Adverse Drug Event Reporting (JADER) database. We conducted a disproportionality analysis using the JADER database from April 2004 to December 2024 to evaluate the cardiovascular and cerebrovascular adverse events associated with intravitreal administration of ranibizumab, aflibercept, and brolucizumab. Time-to-onset distribution and post-onset outcomes were also analyzed. Disproportional signals were observed for cerebral and myocardial infarction associated with ranibizumab and aflibercept, but not with brolucizumab. Time-to-onset analysis showed earlier onset patterns for ranibizumab than for aflibercept, with Weibull shape parameters indicating an early failure-type distribution. Post-event outcome analysis revealed some events resulting in sequelae or death, although many reports had unknown outcomes. This study identified the potential cardiovascular and cerebrovascular safety signals associated with intravitreal administration of ranibizumab and aflibercept. Although brolucizumab showed no significant disproportionality, interpretation requires caution because of limited data. Our findings underscore the importance of continued pharmacovigilance and hypothesis-driven investigations to ensure the safe use of anti-VEGF therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.